A Metabolic Approach to NASH Management

This program will provide the latest information on the pathophysiology of NASH, the interplay between NASH and other components of metabolic syndrome, the importance of early intervention in NASH, emerging metabolic therapies for NASH treatment, and how to develop patient-personalized multidisciplinary treatment plans.

Agenda

  • Welcome and Introduction
  • The Metabolic Nature of Nash
    • NASH pathophysiology
      • Role of genetics, diet, and hormones
      • Insulin resistance and hyperinsulinemia
    • Metabolic syndrome and NASH
      • Obesity as a risk factor for NASH
      • The pathogenic relationship between diabetes and NASH
      • Role of GLP-1 in NASH pathogenesis
  • New Approaches to NASH Treatment
    • Importance of early intervention
    • Current treatment guidelines and pathways
    • Addressing the metabolic complications associated with NASH
    • Mechanism of action and early data with metabolic NASH therapies–
    • GLP-1 receptor agonists
      • PPAR agonists
      • SGLT2 inhibitors
      • Combination regimens
    • Developing patient-personalized treatment plans
    • Q&A and Discussion

Events

Date / Time
Event Details
3/11/2023
12:30 PM

A Metabolic Approach to NASH Management

Bonita Springs, Florida
Hyatt Regency Coconut Point Details

Faculty

Program Chair
Stephen A. Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC

Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom
Chairman, Pinnacle Clinical Research
San Antonio, Texas

Program Chair
Brent Tetri, MD

Professor of Internal Medicine
Director,
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St Louis, Missouri

Goal Statement
The goal of this program is to improve the knowledge and competence of learners on the pathophysiology of NASH, the interplay between NASH and other components of metabolic syndrome, the importance of early intervention in NASH, emerging metabolic therapies for NASH treatment, and how to develop patient personalized multidisciplinary treatment plans, in effort to optimize treatment for patients with NASH.

Target Audience
The intended audience for this educational initiative is gastroenterologists and hepatologists.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the metabolic nature of NASH pathophysiology
  • Explain the relationship between NASH, obesity, and diabetes
  • Determine appropriate strategies for early intervention and treatment in patients with NASH
  • Evaluate emerging metabolic therapies for the management of patients with NASH

Accreditation

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Physician Continuing Medical Education

Credit Designation

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ABIM MOC RECOGNITION STATEMENT

 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Conflicts of Interest 
Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other relevant professional organizations, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of an accredited continuing education program provided by the Potomac Center for Medical Education are required to disclose to PCME all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by PCME in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by PCME to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by PCME.